Abstract
Coronavirus disease (Covid-19) is characterized by an intense inflammatory response and coagulopathy that is associated to a high incidence of thrombotic events with in situ thrombosis of the microcirculation of the lungs and other organs, which is the key event in the pathogenesis of the respiratory and multi-organ failure. These observations have led to to the use of heparin, which has anticoagulant, antiinflammatory and anti-viral properties, as the best agent to treat these patients. Clinical guidelines recommend the use of heparin thromboprophilaxis in these patients, although there is no agreement in the indication, dose and duration of thromboprophylaxis due to lack of randomized studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
